MIEN1

Across TCGA pan-cancer cohorts, MIEN1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIEN1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MIEN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIEN1 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where MIEN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.589	0.873	.014	23	view →
LUAD	OS	Median	All	0.605	0.864	.016	7	view →
PDAC	OS	Tertile	IV	0.293	0.905	.038	6	view →
GBM	DFS	Median	All	0.570	0.772	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIEN1–CCRCC (DFS)

Open the CCRCC breakdown →